These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 18577931)

  • 21. Nigella sativa Oil Reduces Extrapyramidal Symptoms (EPS)-Like Behavior in Haloperidol-Treated Rats.
    Malik T; Hasan S; Pervez S; Fatima T; Haleem DJ
    Neurochem Res; 2016 Dec; 41(12):3386-3398. PubMed ID: 27752803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia.
    Fang M; Chen H; Li LH; Wu R; Li Y; Liu L; Ye M; Huang J; Zhu S; Wang G; Zhang Q; Zheng H; Zhang L; Wang B; Zhou J; Zhao JP
    Int Clin Psychopharmacol; 2012 Mar; 27(2):107-13. PubMed ID: 22233697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST.
    Rybakowski JK; Vansteelandt K; Remlinger-Molenda A; Fleischhacker WW; Kahn RS; Peuskens J;
    Eur Neuropsychopharmacol; 2014 Sep; 24(9):1500-5. PubMed ID: 25085534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypokinetic-rigid extrapyramidal side effects of neuroleptics: the relationship of the silent period in EMG and HVA and 5-HIAA in CSF.
    Yazici O; Hizal A; Eroğlu L; Baslo A; Yazici J
    J Neurol Neurosurg Psychiatry; 1986 Apr; 49(4):448-50. PubMed ID: 2422327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial.
    Wynchank D; Berk M
    Hum Psychopharmacol; 2003 Jun; 18(4):271-5. PubMed ID: 12766931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
    Nasrallah HA; Brecher M; Paulsson B
    Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
    Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.
    Zivković M; Mihaljević-Peles A; Bozina N; Sagud M; Nikolac-Perkovic M; Vuksan-Cusa B; Muck-Seler D
    J Clin Psychopharmacol; 2013 Oct; 33(5):593-9. PubMed ID: 23963056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential effects of a new dibenzo-epine neuroleptic compared with haloperidol. Results of an open and crossover study.
    Mann K; Bartels M; Gärtner HJ; Schied HW; Wagner W; Heimann H
    Pharmacopsychiatry; 1987 Jul; 20(4):155-9. PubMed ID: 2886997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Propranolol (Inderal) for tardive dyskinesia and extrapyramidal side effects from neuroleptics: possible involvement of beta-adrenergic mechanisms.
    Wilbur R; Kulik FA
    Prog Neuropsychopharmacol; 1980; 4(6):627-32. PubMed ID: 6111820
    [No Abstract]   [Full Text] [Related]  

  • 32. Combined treatment of schizophrenic psychoses with haloperidol and valproate.
    Dose M; Hellweg R; Yassouridis A; Theison M; Emrich HM
    Pharmacopsychiatry; 1998 Jul; 31(4):122-5. PubMed ID: 9754845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Testing basic visual functions in the evaluation of extrapyramidal side effects of antipsychotic agents].
    Kéri S; Antal A; Szekeres G; Szendi I; Kovács Z; Janka Z; Benedek G
    Orv Hetil; 1998 Feb; 139(5):235-8. PubMed ID: 9489377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database.
    Fleischhacker WW; Lemmens P; van Baelen B
    Pharmacopsychiatry; 2001 May; 34(3):104-10. PubMed ID: 11434401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.
    Timdahl K; Carlsson A; Stening G
    Hum Psychopharmacol; 2007 Jul; 22(5):315-25. PubMed ID: 17542047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversal of morphine with naloxone precipitates haloperidol-induced extrapyramidal side effects.
    Guo SL; Lin CJ; Huang HH; Chen LK; Sun WZ
    J Pain Symptom Manage; 2006 May; 31(5):391-2. PubMed ID: 16716869
    [No Abstract]   [Full Text] [Related]  

  • 37. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine.
    Kapur S; Roy P; Daskalakis J; Remington G; Zipursky R
    Am J Psychiatry; 2001 Feb; 158(2):311-4. PubMed ID: 11156818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroleptic-induced dysphagia: case report and literature review.
    Dziewas R; Warnecke T; Schnabel M; Ritter M; Nabavi DG; Schilling M; Ringelstein EB; Reker T
    Dysphagia; 2007 Jan; 22(1):63-7. PubMed ID: 17024549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
    Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
    Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study.
    Zhang ZJ; Kang WH; Li Q; Wang XY; Yao SM; Ma AQ
    Schizophr Res; 2006 Dec; 88(1-3):102-10. PubMed ID: 16959472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.